Agenus' BOT+BAL Combination Shows 48% Three-Year Survival in Recurrent Ovarian Cancer

  • Agenus reported 48% estimated three-year overall survival for its BOT+BAL combination in recurrent ovarian cancer patients, unchanged from the two-year estimate.
  • The study included 35 evaluable patients, all of whom had received prior platinum chemotherapy, with 77% having also received bevacizumab and 57% a PARP inhibitor.
  • 25% of treated patients (11 of 44) were alive and off all therapy at the last follow-up.
  • The results were presented at the 2026 IGCS Annual Global Meeting in Montréal, Canada.

Agenus' data suggests that its BOT+BAL combination may offer lasting benefits in recurrent ovarian cancer, a population where conventional immunotherapies have largely failed. The results align with a broader trend of exploring novel immune checkpoint inhibitors to address treatment-resistant cancers. The durability of responses in heavily pretreated patients could position Agenus as a key player in the immuno-oncology space, particularly if these findings hold up in larger, controlled studies.

Clinical Efficacy
Whether the durable survival benefits observed in heavily pretreated ovarian cancer patients will translate into earlier-stage settings.
Regulatory Pathway
The pace at which Agenus advances BOT+BAL through subsequent clinical trials and potential regulatory filings.
Market Differentiation
How Agenus positions BOT+BAL against existing and emerging immuno-oncology therapies in recurrent ovarian cancer.